Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.

Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, Alangaden GJ, Chemaly RF, Petersen F, Chao N, Klein J, Sprague K, Villano SA, Boeckh M.

Blood. 2008 Jun 1;111(11):5403-10. doi: 10.1182/blood-2007-11-121558. Epub 2008 Feb 19.

2.

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.

Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M; Maribavir 1263-300 Clinical Study Group.

Lancet Infect Dis. 2011 Apr;11(4):284-92. doi: 10.1016/S1473-3099(11)70024-X. Epub 2011 Mar 21. Erratum in: Lancet Infect Dis. 2011 May;11(5):343.

PMID:
21414843
3.

Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial.

Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA, Clough L, Avery R, Limaye AP, Ericzon BG, Navasa M, Troisi RI, Chen H, Villano SA, Uknis ME; 1263-301 Clinical Study Group.

Am J Transplant. 2012 Nov;12(11):3021-30. doi: 10.1111/j.1600-6143.2012.04231.x. Epub 2012 Sep 4. Erratum in: Am J Transplant. 2013 Feb;13(2):529.

4.

Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263.

[No authors listed]

Drugs R D. 2007;8(3):188-92. Review.

PMID:
17472414
5.

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA.

Biol Blood Marrow Transplant. 2001;7(6):343-51.

6.

Maribavir: a novel antiviral agent with activity against cytomegalovirus.

Trofe J, Pote L, Wade E, Blumberg E, Bloom RD.

Ann Pharmacother. 2008 Oct;42(10):1447-57. doi: 10.1345/aph.1L065. Epub 2008 Aug 12. Review.

PMID:
18698013
7.

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.

Avery RK, Marty FM, Strasfeld L, Lee I, Arrieta A, Chou S, Tatarowicz W, Villano S.

Transpl Infect Dis. 2010 Dec;12(6):489-96. doi: 10.1111/j.1399-3062.2010.00550.x.

PMID:
20682012
8.

CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.

Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Momméja-Marin H, Boeckh M; CMX001-201 Clinical Study Group.

N Engl J Med. 2013 Sep 26;369(13):1227-36. doi: 10.1056/NEJMoa1303688.

9.

In vitro studies of the impact of maribavir on CMV-specific cellular immune responses.

Stachel D, Stevens-Ayers T, Boeckh M.

J Clin Virol. 2016 Feb;75:53-9. doi: 10.1016/j.jcv.2015.12.012. Epub 2015 Dec 31.

PMID:
26780109
10.

Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.

Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, Kölling K, Stobernack HP, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Champlin RE, Ehninger G; AIC246 Study Team.

N Engl J Med. 2014 May 8;370(19):1781-9. doi: 10.1056/NEJMoa1309533.

12.

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial.

Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin RE.

Ann Intern Med. 1993 Feb 1;118(3):179-84.

PMID:
8380243
13.

New developments in the management of cytomegalovirus infection after solid organ transplantation.

Eid AJ, Razonable RR.

Drugs. 2010 May 28;70(8):965-81. doi: 10.2165/10898540-000000000-00000. Review.

PMID:
20481654
14.

A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients.

Pescovitz MD, Bloom R, Pirsch J, Johnson J, Gelone S, Villano SA.

Am J Transplant. 2009 Oct;9(10):2324-30. doi: 10.1111/j.1600-6143.2009.02768.x. Epub 2009 Aug 6.

15.

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant.

Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD.

Ann Intern Med. 1993 Feb 1;118(3):173-8.

PMID:
8380242
16.
17.

Cytomegalovirus infection after liver transplantation: current concepts and challenges.

Razonable RR.

World J Gastroenterol. 2008 Aug 21;14(31):4849-60. Review.

18.

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA.

Lancet. 1997 Dec 13;350(9093):1729-33. Erratum in: Lancet 1998 Feb 7;351(9100):454.

PMID:
9413463
19.

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C.

N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.

PMID:
29211658
20.

Cytomegalovirus.

Griffiths P, Lumley S.

Curr Opin Infect Dis. 2014 Dec;27(6):554-9. doi: 10.1097/QCO.0000000000000107. Review.

PMID:
25304390

Supplemental Content

Support Center